BioTuesdays

Category - Markets

Markets

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...

May 6, 2020
Neuronetics Logo
Markets

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

May 5, 2020
Cutera Logo
Markets

Stifel ups Cutera to buy from hold; PT $26

Stifel upgraded Cutera (NASDAQ:CUTR) to “buy” from “hold” with a $26 price target, citing a solid product pipeline, compelling valuation and a recently strengthened balance sheet. The stock closed at $12.90 on May 4...

May 5, 2020
PolarityTE Logo
Markets

HCW cuts PolarityTE to neutral and removes PT

H.C. Wainwright downgraded PolarityTE (NASDAQ:PTE) to “neutral” from “buy” and removed its price target, citing the clinical and regulatory risk from a strategy shift for its wound closure product, SkinTE. The stock...

May 4, 2020
Keros Therapeutics Logo
Markets

Analysts start Keros Therapeutics at buy, OP

Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...

May 4, 2020
Xenetic Biosciences Logo
Markets

HCW starts Xenetic Biosciences at buy; PT $2

H.C. Wainwright initiated coverage of Xenetic Biosciences (NASDAQ:XBIO) with a “buy” rating and price target of $2. The stock closed at 86 cents on May 1. The main focus of the company is development of XCART, a CAR-T...

May 4, 2020
Axcella Logo
Markets

BTIG starts Axcella Health at buy; PT $10

BTIG launched coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $10 price target. The stock closed at $4.66 on April 30. “We view Axcella’s calculated approach to correcting metabolic diseases with...

May 1, 2020
Mersana Therapeutics Logo
Markets

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

April 29, 2020